| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70a0919564cd6d43eac5a20c7ce430c0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate |
1993-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0f8ea4985c9d223f37ab025821bdfbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96a1556ba74d3774d455aa3e42a6b16a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_048dd3e60bcfc7491b539df7268f0784 |
| publicationDate |
1993-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9319762-A1 |
| titleOfInvention |
Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) |
| abstract |
The present invention relates to pharmaceutical compositions useful for the treatment of subjects suffering from an infection or disease caused by the hepatitis B virus (HBV). In particular, it has been discovered that the administration of low dosage amounts of 1-(2'-deoxy-2'-fluoro-$g(b)-D-arabinofuranosyl)-5-iodouracil (FIAU) to humans chronically infected with HBV is effective to reduce drastically circulating markers associated with HBV. The present invention is also directed to methods of the preparation of pharmaceutical antiviral compositions. |
| priorityDate |
1992-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |